Veeva Systems Shares Drop After Management Acknowledges Competitive Losses in Key Markets

Veeva Systems (VEEV) experienced a notable stock retreat after senior leadership disclosed a strategic setback in its core healthcare IT business. During the company’s quarterly update, executives confirmed that 17% of proposed enterprise deals in the pharmaceutical and life sciences sectors were lost to competitors, a sharp increase from the 6% loss rate observed in the same period last year. The company attributed the erosion to stronger competitive pressure from cloud and compliance platforms offered by Microsoft (MSFT) and Intel (INTC), which have accelerated their enterprise-grade solutions tailored for regulated environments. The disclosure comes amid growing scrutiny over Veeva’s market dominance in lifecycle management software. Despite maintaining over $1.2 billion in annual recurring revenue, the firm reported a 12% year-over-year decline in new deal acquisition volume. This marks the first such drop in over three years and has raised concerns about the sustainability of its growth trajectory. Analysts noted that Microsoft’s Azure-based compliance tools and Intel’s AI-driven data integrity systems have begun to outperform Veeva’s legacy platforms in customer evaluations. Investors reacted swiftly, with VEEV’s share price falling 8.4% in after-hours trading. The sell-off also impacted broader healthcare IT indices, with related equities such as Cerner (CERN) and Thermo Fisher Scientific (TMO) showing modest declines. The market is now reassessing Veeva’s long-term differentiation, particularly as cloud-native competitors gain traction with digital transformation initiatives across global pharma firms.